Vimarsana
Biggest News Aggregation in the World

Therapeutics Summit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Therapeutics Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Therapeutics Summit Today - Breaking & Trending Today

Veru to Present at the GLP-1 Based Therapeutics Summit - Vimarsana News

Veru to Present at the GLP-1 Based Therapeutics Summit

Published: May 2, 2024

MIAMI, FL, May 02, 2024 -- Veru Inc. , a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and...

Source: marketscreener.com
Related Topics:
United StatesSamuel FischGlobenewswire IncCompany FormVeru IncCorporate CommunicationsTherapeutics SummitAvoid Muscle LossAugment Fat Loss When CombinedPotentially Higher Quality WeightEnobosarm PhaseInternal CondomPrivate Securities Litigation Reform ActMedia ContactInvestor Relations
Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and Eur - Vimarsana News

Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and Eur

Published: August 23, 2023

TÜBINGEN, Germany, Aug. 23, 2023 /PRNewswire/ -- Acousia Therapeutics GmbH to sharekey learningsand data...

Source: europapress.es
Related Topics:
City OfUnited KingdomUnited StatesJonas Dyhrfjeld JohnsenTrends In Drug Development For AgeHuman Hearing Development Impacts Preclinical EfficacyCare ResearchTranslational Hearing Research GroupUniversity College London Ear InstituteHearing Research Center Department Of OtolaryngologyNational Institute For HealthRoyal National Institute For Deaf PeopleTherapeutics GmbhAcousia TherapeuticsAnnual Inner Ear Disorders Therapeutics SummitPreclinical Study DesignEnhancing ProbabilityDrug DevelopmentAge Related HearingChief Development OfficerChosen Animal ModelLessons LearnedLocally AdministeredTherapeutics SummitRoyal National Institute
- Vimarsana News

Published: August 23, 2023

Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry …

Source: ots.at
Related Topics:
United StatesCity OfUnited KingdomJonas Dyhrfjeld JohnsenUniversity College London Ear InstituteTrends In Drug Development For AgeRoyal National Institute For Deaf PeopleHearing Research Center Department Of OtolaryngologyTranslational Hearing Research GroupNational Institute For HealthHuman Hearing Development Impacts Preclinical EfficacyCare ResearchAcousia TherapeuticsAcousia Therapeutics GmbhAnnual Inner Ear Disorders Therapeutics SummitPreclinical Study DesignEnhancing ProbabilityDrug DevelopmentAge Related HearingChief Development OfficerChosen Animal ModelLessons LearnedLocally AdministeredTherapeutics SummitRoyal National Institute
Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September - Vimarsana News

Hearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September

Published: August 23, 2023

/PRNewswire/ -- Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late...

Source: prnewswire.com
Related Topics:
City OfUnited KingdomUnited StatesJonas Dyhrfjeld JohnsenCare ResearchHuman Hearing Development Impacts Preclinical EfficacyNational Institute For HealthTranslational Hearing Research GroupHearing Research Center Department Of OtolaryngologyTrends In Drug Development For AgeUniversity College London Ear InstituteRoyal National Institute For Deaf PeopleTherapeutics GmbhAcousia TherapeuticsAnnual Inner Ear Disorders Therapeutics SummitPreclinical Study DesignEnhancing ProbabilityDrug DevelopmentAge Related HearingChief Development OfficerChosen Animal ModelLessons LearnedLocally AdministeredTherapeutics SummitRoyal National Institute
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2022 Results - Earnings Call Transcript - Vimarsana News

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2022 Results - Earnings Call Transcript

Published: May 14, 2022

Applied DNA Sciences, Inc. (NASDAQ:NASDAQ:APDN) Q2 2022 Earnings Conference Call May 12, 2022, 04:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief...

Source: seekingalpha.com
Related Topics:
New YorkUnited StatesWhite HouseDistrict Of ColumbiaLong IslandBeth JantzenJames HaywardJon SalmansonJudy MurrahJason MccartyClay ShorrockJonathan AschoffCompany ParticipantsSciences IncClinical LaboratoryAmerican SocietyMaxim GroupYork State Department Of HealthHead Of Business DevelopmentConference Call MayChief ExecutiveFiscal Second QuarterResults ConferenceSanjay HurryInvestor Relations